A positive-margin resection model recreates the postsurgical tumor microenvironment and is a reliable model for adjuvant therapy evaluation

Cancer Biology and Therapy

Volumn 13, Issue 9, 2012, Pages 745-755

  Predina, Jarrod D ^a   Judy, Brendan ^a   Fridlender, Zvi G ^b   Aliperti, Louis A ^a   Madajewski, Brian ^a   Kapoor, Veena ^a   Cheng, Guanjun ^a   Quatromoni, Jon ^a   Okusanya, Olugbenga ^a   Singhal, Sunil ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Adjuvant therapy; Cancer recurrence; Immunotherapy; Oncology; Surgical model; Tumor microenvironment

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER MODEL; CANCER RECURRENCE; CANCER RELAPSE; CANCER SURGERY; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME INHIBITION; FEMALE; MOUSE; NONHUMAN; POSTOPERATIVE CARE; PROGRESSION FREE SURVIVAL; RELIABILITY; SURGICAL TECHNIQUE; TUMOR MICROENVIRONMENT; WOUND DEHISCENCE; WOUND HEALING;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CHEMOTHERAPY, ADJUVANT; CYCLOOXYGENASE 2 INHIBITORS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNITY, INNATE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS; POSTOPERATIVE COMPLICATIONS; PYRAZOLES; SULFONAMIDES; SURGICAL WOUND DEHISCENCE; TRANSFORMING GROWTH FACTOR BETA; TUMOR BURDEN; TUMOR MICROENVIRONMENT; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84863489042     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.20557     Document Type: Article

References (43)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61:69-90; PMID:21296855; http://dx.doi.org/ 10.3322/caac.20107.
2. Predina JD, Judy B, Aliperti LA, Fridlender ZG, Blouin A, Kapoor V, et al. Neoadjuvant in situ gene-mediated cytotoxic immunotherapy improves postoperative outcomes in novel syngeneic esophageal carcinoma models. Cancer Gene Ther 2011; 18:871-83; PMID:21869822; http://dx.doi.org/10.1038/cgt.2011.56.
3. Roh JL, Sung MW, Park SW, Heo DS, Lee DW, Kim KH. Celecoxib can prevent tumor growth and distant metastasis in postoperative setting. Cancer Res 2004; 64:3230-5; PMID:15126364; http://dx.doi.org/10.1158/0008-5472.CAN-03-3050.
4. Schultz GS, White M, Mitchell R, Brown G, Lynch J, Twardzik DR, et al. Epithelial wound healing enhanced by transforming growth factoralpha and vaccinia growth factor. Science 1987; 235:350-2; PMID:3492044; http://dx.doi.org/10.1126/science.3492044.
5. Schreiber K, Rowley DA, Riethmüller G, Schreiber H. Cancer immunotherapy and preclinical studies: why we are not wasting our time with animal experiments. Hematol Oncol Clin North Am 2006; 20:567-84; PMID:16762725; http://dx.doi.org/10.1016/j.hoc.2006.03.001.
6. Smith MJ, Culhane AC, Killeen S, Kelly MA, Wang JH, Cotter TG, et al. Mechanisms driving local breast cancer recurrence in a model of breast-conserving surgery. Ann Surg Oncol 2008; 15:2954-64; PMID:18622646; http://dx.doi.org/10.1245/s10434-008-0037-5.
7. Grinshtein N, Bridle B, Wan Y, Bramson JL. Neoadjuvant vaccination provides superior protection against tumor relapse following surgery compared with adjuvant vaccination. Cancer Res 2009; 69:3979-85; PMID:19383917; http://dx.doi.org/10.1158/0008-5472.CAN-08-3385.
8. Broomfield S, Currie A, van der Most RG, Brown M, van Bruggen I, Robinson BW, et al. Partial, but not complete, tumor-debulking surgery promotes protective antitumor memory when combined with chemotherapy and adjuvant immunotherapy. Cancer Res 2005; 65:7580-4; PMID:16140921.
9. DeLisser HM, Keirns CC, Clinton EA, Margolis ML. "The air got to it:" exploring a belief about surgery for lung cancer. J Natl Med Assoc 2009; 101:765-71; PMID:19715038.
10. Stuelten CH, Barbul A, Busch JI, Sutton E, Katz R, Sato M, et al. Acute wounds accelerate tumorigenesis by a T cell-dependent mechanism. Cancer Res 2008; 68:7278-82; PMID:18794114; http://dx.doi.org/10.1158/0008-5472.CAN-08- 1842.
11. Rofstad EK, Mathiesen B, Henriksen K, Kindem K, Galappathi K. The tumor bed effect: increased metastatic dissemination from hypoxia-induced upregulation of metastasis-promoting gene products. Cancer Res 2005; 65:2387-96; PMID:15781654; http://dx.doi.org/10.1158/0008-5472.CAN-04-3039.
12. Alsousou J, Thompson M, Hulley P, Noble A, Willett K. The biology of platelet-rich plasma and its application in trauma and orthopaedic surgery: a review of the literature. J Bone Joint Surg Br 2009; 91:987-96; PMID:19651823; http://dx.doi.org/10.1302/0301-620X.91B8.22546.
13. Suzuki E, Kapoor V, Cheung HK, Ling LE, DeLong PA, Kaiser LR, et al. Soluble type II transforming growth factorbeta receptor inhibits established murine malignant mesothelioma tumor growth by augmenting host antitumor immunity. Clin Cancer Res 2004; 10:5907-18; PMID:15355924; http://dx.doi.org/10. 1158/1078-0432.CCR-03-0611.
14. Suzuki E, Kim S, Cheung HK, Corbley MJ, Zhang X, Sun L, et al. A novel small-molecule inhibitor of transforming growth factorbeta type I receptor kinase (SM16) inhibits murine mesothelioma tumor growth in vivo and prevents tumor recurrence after surgical resection. Cancer Res 2007; 67:2351-9; PMID:17332368; http://dx.doi.org/10.1158/0008-5472.CAN-06-2389.
15. Ueda R, Fujita M, Zhu X, Sasaki K, Kastenhuber ER, Kohanbash G, et al. Systemic inhibition of transforming growth factorbeta in glioma-bearing mice improves the therapeutic efficacy of glioma-associated antigen peptide vaccines. Clin Cancer Res 2009; 15:6551-9; PMID:19861464; http://dx.doi.org/10.1158/1078- 0432.CCR-09-1067.
16. Kim S, Buchlis G, Fridlender ZG, Sun J, Kapoor V, Cheng G, et al. Systemic blockade of transforming growth factorbeta signaling augments the efficacy of immunogene therapy. Cancer Res 2008; 68:10247-56; PMID:19074893; http://dx.doi.org/10.1158/0008-5472.CAN-08-1494.
17. Lee GT, Hong JH, Kwak C, Woo J, Liu V, Lee C, et al. Effect of dominant negative transforming growth factorbeta receptor type II on cytotoxic activity of RAW 264.7, a murine macrophage cell line. Cancer Res 2007; 67:6717-24; PMID:17638882; http://dx.doi.org/10.1158/0008-5472.CAN-06-4263.
18. + T cell-mediated tumor vaccine efficacy by an anti-transforming growth factorbeta monoclonal antibody. Clin Cancer Res 2009; 15:6560-9; PMID:19861451; http://dx.doi.org/10.1158/1078-0432. CCR-09-1066.
19. Fontana A, Galli L, Fioravanti A, Orlandi P, Galli C, Landi L, et al. Clinical and pharmacodynamic evaluation of metronomic cyclophosphamide, celecoxib and dexamethasone in advanced hormone-refractory prostate cancer. Clin Cancer Res 2009; 15:4954-62; PMID:19622584; http://dx.doi.org/10.1158/1078- 0432.CCR-08-3317.
20. Hahn T, Alvarez I, Kobie JJ, Ramanathapuram L, Dial S, Fulton A, et al. Short-term dietary administration of celecoxib enhances the efficacy of tumor lysate-pulsed dendritic cell vaccines in treating murine breast cancer. Int J Cancer 2006; 118:2220-31; PMID:16331615; http://dx.doi.org/10.1002/ijc.21616.
21. Howe LR, Subbaramaiah K, Patel J, Masferrer JL, Deora A, Hudis C, et al. Celecoxib, a selective cyclooxygenase 2 inhibitor, protects against human epidermal growth factor receptor 2 (HER-2)/neu-induced breast cancer. Cancer Res 2002; 62:5405-7; PMID:12359744.
22. Haas AR, Sun J, Vachani A, Wallace AF, Silverberg M, Kapoor V, et al. Cycloxygenase-2 inhibition augments the efficacy of a cancer vaccine. Clin Cancer Res 2006; 12:214-22; PMID:16397045; http://dx.doi.org/10.1158/1078-0432. CCR-05-1178.
23. Kruklitis RJ, Singhal S, Delong P, Kapoor V, Sterman DH, Kaiser LR, et al. Immuno-gene therapy with interferonbeta before surgical debulking delays recurrence and improves survival in a murine model of malignant mesothelioma. J Thorac Cardiovasc Surg 2004; 127:123-30; PMID:14752422; http://dx.doi.org/10. 1016/j.jtcvs.2003.08.034.
24. Bursuker I, North RJ. Generation and decay of the immune response to a progressive fibrosarcoma. II. Failure to demonstrate postexcision immunity after the onset of T cell-mediated suppression of immunity. J Exp Med 1984; 159:1312-21; PMID:6232336; http://dx.doi.org/10.1084/jem.159.5.1312.
25. Shakhar G, Ben-Eliyahu S. Potential prophylactic measures against postoperative immunosuppression: could they reduce recurrence rates in oncological patients? Ann Surg Oncol 2003; 10:972-92; PMID:14527919; http://dx.doi.org/10.1245/ASO.2003.02.007.
26. Hoffman RM. The multiple uses of fluorescent proteins to visualize cancer in vivo. Nat Rev Cancer 2005; 5:796-806; PMID:16195751; http://dx.doi.org/10. 1038/nrc1717.
27. Kishimoto H, Zhao M, Hayashi K, Urata Y, Tanaka N, Fujiwara T, et al. In vivo internal tumor illumination by telomerase-dependent adenoviral GFP for precise surgical navigation. Proc Natl Acad Sci USA 2009; 106:14514-7; PMID:19706537; http://dx.doi.org/10.1073/pnas.0906388106.
28. Teicher BA. Transforming growth factorbeta and the immune response to malignant disease. Clin Cancer Res 2007; 13:6247-51; PMID:17975134; http://dx.doi.org/10.1158/1078-0432.CCR-07-1654.
29. Yang L, Pang Y, Moses HL. TGFbeta and immune cells: an important regulatory axis in the tumor microenvironment and progression. Trends Immunol 2010; 31:220-7; PMID:20538542; http://dx.doi.org/10.1016/j.it.2010.04.002.
30. Wallace A, Kapoor V, Sun J, Mrass P, Weninger W, Heitjan DF, et al. Transforming growth factorbeta receptor blockade augments the effectiveness of adoptive T-cell therapy of established solid cancers. Clin Cancer Res 2008; 14:3966-74; PMID:18559619; http://dx.doi.org/10.1158/1078-0432.CCR-08-0356.
31. Fridlender ZG, Sun J, Kim S, Kapoor V, Cheng G, Ling L, et al. Polarization of tumor-associated neutrophil phenotype by TGFbeta: "N1" versus "N2" TAN. Cancer Cell 2009; 16:183-94; PMID:19732719; http://dx.doi.org/10.1016/j.ccr.2009.06.017.
32. DeLong P, Tanaka T, Kruklitis R, Henry AC, Kapoor V, Kaiser LR, et al. Use of cyclooxygenase-2 inhibition to enhance the efficacy of immunotherapy. Cancer Res 2003; 63:7845-52; PMID:14633712.
33. Tanaka T, Delong PA, Amin K, Henry A, Kruklitis R, Kapoor V, et al. Treatment of lung cancer using clinically relevant oral doses of the cyclooxygenase-2 inhibitor rofecoxib: potential value as adjuvant therapy after surgery. Ann Surg 2005; 241:168-78; PMID:15622005.
34. Kim SK, Wu X, Ragupathi G, Gathuru J, Koide F, Cheung NK, et al. Impact of minimal tumor burden on antibody response to vaccination. Cancer Immunol Immunother 2011; 60:621-7; PMID:21267719; http://dx.doi.org/10.1007/s00262-011- 0975-9.
35. Wang XJ, Han G, Owens P, Siddiqui Y, Li AG. Role of TGFbeta-mediated inflammation in cutaneous wound healing. J Investig Dermatol Symp Proc 2006; 11:112-7; PMID:17069018; http://dx.doi.org/10.1038/sj.jidsymp.5650004.
36. Martinez-Ferrer M, Afshar-Sherif AR, Uwamariya C, de Crombrugghe B, Davidson JM, Bhowmick NA. Dermal transforming growth factorbeta responsiveness mediates wound contraction and epithelial closure. Am J Pathol 2010; 176:98-107; PMID:19959810; http://dx.doi.org/10.2353/ajpath.2010.090283.
37. Taketo MM. Cyclooxygenase-2 inhibitors in tumorigenesis (part I). J Natl Cancer Inst 1998; 90:1529-36; PMID:9790545; http://dx.doi.org/10.1093/jnci/90. 20.1529.
38. Taketo MM. Cyclooxygenase-2 inhibitors in tumorigenesis (Part II). J Natl Cancer Inst 1998; 90:1609-20; PMID:9811310; http://dx.doi.org/10.1093/jnci/90. 21.1609.
39. Lacchetti C, Ioannidis J, Guyatt G. Surprising results of randomized trials. Most Major Basic Science and Preclinical Promises for Effective Interventions Disapppoint in Clinical Trials. In: Guyatt G RD, Meade MO, Cook DJ, Ed. Users' Guides to the Medical Literature: A Manual for Evidence-Based Clinical Practice. New York: McGraw-Hill 2008.
40. Davis MR, Manning LS, Whitaker D, Garlepp MJ, Robinson BW. Establishment of a murine model of malignant mesothelioma. Int J Cancer 1992; 52:881-6; PMID:1459729; http://dx.doi.org/10.1002/ijc.2910520609.
41. Opitz OG, Harada H, Suliman Y, Rhoades B, Sharpless NE, Kent R, et al. A mouse model of human oralesophageal cancer. J Clin Invest 2002; 110:761-9; PMID:12235107.
42. Lin KY, Guarnieri FG, Staveley-O'Carroll KF, Levitsky HI, August JT, Pardoll DM, et al. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res 1996; 56:21-6; PMID:8548765.
43. Dasch JR, Pace DR, Waegell W, Inenaga D, Ellingsworth L. Monoclonal antibodies recognizing transforming growth factorbeta. Bioactivity neutralization and transforming growth factorbeta 2 affinity purification. J Immunol 1989; 142:1536-41; PMID:2537357.